Response to antiretroviral treatment in HIV-1-infected individuals with allelic variants of the multidrug resistance transporter 1: a pharmacogenetics study

HIV-1-infected patients vary considerably by their response to antiretroviral treatment, drug concentrations in plasma, toxic events, and rate of immune recovery. Describes a pharmacogenetics study to analyse the association between response to antiretroviral treatment and allelic variants of severa...

Full description

Saved in:
Bibliographic Details
Published inThe Lancet (British edition) Vol. 5; pp. 30 - 36
Main Authors Fellay, J, Marzolini, C, Meaden, E R, Back, D J, Buclin, T, Chave, J-P, Decosterd, L A, Furrer, H, Opravil, M, Pantaleo, G, Retelska, D, Ruiz, L, Schinkel, A H, Vernazza, P, Eap, C B, Telenti, A
Format Journal Article
LanguageEnglish
Published 01.01.2002
Subjects
Antiretroviral therapy
Genetic factors
Human immunodeficiency virus
Multiple drugs
Resistance
Treatment
Online AccessGet full text

Cover

More Information
Summary:HIV-1-infected patients vary considerably by their response to antiretroviral treatment, drug concentrations in plasma, toxic events, and rate of immune recovery. Describes a pharmacogenetics study to analyse the association between response to antiretroviral treatment and allelic variants of several genes. Found that the polymorphism MDR1 3435 C/T predicts immune recovery after initiation of antiretroviral treatment. This finding suggests that P-glycoprotein has an important role in admittance of antiretroviral drugs to restricted compartments in vivo. (Original abstract - amended)
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
content type line 23
ObjectType-Feature-2
ISSN:0140-6736